Evidence map›Paper›PMID 42045397›Full record

ArticleScientific reports2026

Gallic acid chemoprevention of oral carcinogenesis is associated with HSD11β2 upregulation and immune remodeling.

Puja Upadhaya, Felipe F Lamenza, Ravi Ramalingam, Kishan Kumar Nyati, Sushmitha Jagadeesha, Suvekshya Shrestha, Reegan Kehres, Natalie Kazmierowicz, Sonali Dasari, Shaheer Masood and 3 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Puja UpadhayaDepartment of Pathology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, 242A Evans Hall, 520 King Ave., Columbus, OH, 43201, USA.
Felipe F LamenzaDepartment of Pathology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, 242A Evans Hall, 520 King Ave., Columbus, OH, 43201, USA.
Ravi RamalingamDepartment of Pathology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, 242A Evans Hall, 520 King Ave., Columbus, OH, 43201, USA.
Kishan Kumar NyatiDepartment of Pathology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, 242A Evans Hall, 520 King Ave., Columbus, OH, 43201, USA.
Sushmitha JagadeeshaDepartment of Pathology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, 242A Evans Hall, 520 King Ave., Columbus, OH, 43201, USA.
Suvekshya ShresthaDepartment of Pathology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, 242A Evans Hall, 520 King Ave., Columbus, OH, 43201, USA.
Reegan KehresDepartment of Pathology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, 242A Evans Hall, 520 King Ave., Columbus, OH, 43201, USA.
Natalie KazmierowiczDepartment of Pathology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, 242A Evans Hall, 520 King Ave., Columbus, OH, 43201, USA.
Sonali DasariDepartment of Pathology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, 242A Evans Hall, 520 King Ave., Columbus, OH, 43201, USA.
Shaheer MasoodDepartment of Pathology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, 242A Evans Hall, 520 King Ave., Columbus, OH, 43201, USA.
Peyton RothDepartment of Pathology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, 242A Evans Hall, 520 King Ave., Columbus, OH, 43201, USA.
Hasan PrachaDepartment of Pathology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, 242A Evans Hall, 520 King Ave., Columbus, OH, 43201, USA.
Steve OghumuDepartment of Pathology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, 242A Evans Hall, 520 King Ave., Columbus, OH, 43201, USA. oghumu.1@osu.edu.

Funding

The oral glucocorticoid system in oral carcinogenesis and its modulation for improved treatment outcomesR01DE033906 · NIDCR · OHIO STATE UNIVERSITY · PI Steve Onyeka Oghumu · 2024 to 2026
$1.9M
American Cancer Society RSG-19079-01-TBGNIH HHS R01DE033906
6 · The paper itself

Abstract

Naturally derived phytochemicals such as gallic acid (GA) exhibit multitargeted anticancer properties and favorable safety profiles, yet the molecular mechanisms underlying their chemopreventive effects in head and neck squamous cell carcinoma (HNSCC) remain incompletely defined. Using a 4-nitroquinoline-1-oxide (4NQO)-induced oral carcinogenesis mouse model, we evaluated GA's effects on tumor progression, immune modulation, and stress-hormone-related pathways. Phenotypic outcomes were assessed by histopathology, proliferation markers, and in vitro cytotoxicity assays. Transcriptomic changes were profiled by RNA sequencing, pathway enrichment and validation using RT-qPCR, Western blotting, ELISA, and flow cytometry. GA selectively inhibited proliferation of HNSCC cell lines (CAL27, SCC83) while sparing normal oral epithelial cells (TE1177). In vivo, GA reduced tumor burden and histopathologic severity without affecting body weight. RNA-seq analysis revealed coordinated modulation of immune and stress-response pathways, including upregulation of Carmil2, Cd27, and Cd209d and downregulation of Fos, Pappa, and Hif1a. GA increased HSD11β2 expression in vitro and in vivo and reduced cortisol in cAMP-stimulated HNSCC cells, findings consistent with reduced local glucocorticoid signaling. GA also increased IL-2 and decreased IL-10 in T cells, reduced monocytic MDSCs, and lowered PD-L1 on pro-inflammatory macrophages. Together, these findings identify HSD11β2/glucocorticoid metabolism as a potential axis associated with GA-mediated oral cancer chemoprevention.

Indexed as

Anticarcinogenic AgentsCarcinogenesisGallic AcidMouth Neoplasms4-Nitroquinoline-1-oxideAnimalsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMiceUp-Regulation4-Nitroquinoline-1-oxideAnticarcinogenic AgentsGallic Acid11β-hydroxysteroid dehydrogenase type 24-nitroquinoline-1-oxideChemopreventionGallic acidGlucocorticoidsHead and neck squamous cell carcinomaImmune modulation

Identifiers

PMID42045397
PMCPMC13284332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.